Gold coordination complexes as anticancer agents

Irena Kostova1

  • 1Department of Chemistry, Faculty of Pharmacy, Medical University, 2 Dunav St., Sofia 1000, Bulgaria. irenakostova@yahoo.com

Insights

Gold(III) complexes show promise as anticancer agents, potentially offering reduced toxicity compared to platinum drugs. Further study of gold complexes with various ligands is needed to understand their anticancer properties.

Area of Science:

  • Inorganic chemistry
  • Medicinal chemistry
  • Biochemistry

Background:

  • Metal ions interact with nucleic acids, influencing their function.
  • Platinum complexes are successful anticancer drugs.
  • Gold(I) and gold(III) complexes are investigated as potential anticancer agents due to similarities with platinum.

Purpose of the Study:

  • To explore the potential of gold(III) complexes as anticancer agents.
  • To investigate the interactions of gold complexes with ligands.
  • To understand the structure-activity relationship of gold-based anticancer drugs.

Main Methods:

  • Literature review on gold and platinum complexes in chemotherapy.
  • Analysis of metal ion-base interactions.
  • Study of coordination chemistry and complex stability.

Main Results:

  • Gold(III) complexes are isoelectronic and isostructural with platinum(II) complexes.
  • Gold(III) complexes can form strong covalent attachments to biological targets.
  • Gold complexes offer potential for decreased toxicity compared to platinum drugs.

Conclusions:

  • Gold(III) complexes are attractive candidates for anticancer drug development.
  • Understanding gold complex interactions with ligands is crucial for optimizing anticancer efficacy.
  • Further research into gold complexes could lead to novel chemotherapy agents with improved safety profiles.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Complexometric Titration: Ligands00:43

Complexometric Titration: Ligands

Different monodentate and polydentate ligands are used as complexing agents in complexometric titration reactions. The formation of complexes by mono- and bidentate ligands involves two or more intermediate steps, limiting their use as complexing agents. In comparison, polydentate ligands can form complexes with metal ions in a single-step process, facilitating sharper end points. This means polydentate ligands, such as amino carboxylic acid derivatives, are most commonly employed in...